Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human...

Area of Science:

• Bone biology and pharmacology
• Cellular and molecular medicine
• Drug effects on bone metabolism

Background:

• Bisphosphonates (BPs) are primary treatments for bone disorders, primarily targeting osteoclasts.
• The specific effects of BPs on osteoblasts remain incompletely understood.
• Investigating nitrogen-containing bisphosphonates' impact on osteoblasts is crucial for understanding bone remodeling.

Purpose of the Study:

• To investigate the effects of Alendronate (ALN) and Zoledronate (ZOL) on human primary pre-osteoblasts.
• To elucidate the direct impact of these nitrogen-containing bisphosphonates on bone-forming cells.
• To assess cellular viability, function, and mediator release in response to ALN and ZOL.

Main Methods:

• Treatment of human primary pre-osteoblasts with varying concentrations of ALN and ZOL.
• Assessment of cell viability and alkaline phosphatase activity.
• Analysis of mineralized nodule deposition, pro-inflammatory mediator release (TNFα, IL-1β), and osteoblastogenesis inhibitors (DKK-1, Sclerostin).
• Evaluation of collagen type I, Osteopontin, and SPARC gene expression.

Main Results:

• Alendronate and Zoledronate inhibited cell viability and alkaline phosphatase activity at µM concentrations.
• A trend towards reduced mineralized nodule deposition was observed.
• Low doses of ALN and ZOL increased pro-inflammatory mediators (TNFα, IL-1β) and osteoblastogenesis inhibitors (DKK-1, Sclerostin).
• ALN and 10⁻⁷M ZOL decreased Collagen type I and Osteopontin expression, while stimulating SPARC.

Conclusions:

• Nitrogen-containing bisphosphonates exert a direct inhibitory effect on human primary pre-osteoblasts.
• These drugs impact osteoblast viability, function, and the expression of key bone-related proteins.
• Findings suggest a potential direct mechanism of action on bone formation, beyond osteoclast inhibition.